Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742027 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
A Phase 2 study of Classical Hodgkin's Lymphoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT00742027 is a Phase 2 study of Classical Hodgkin's Lymphoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 129 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT00742027, a Phase 2 study of Classical Hodgkin's Lymphoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.
Conditions Studied
Interventions
- DRUG Panobinostat
Study Locations (20)
Texas
- University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3) - Houston
- The Methodist Hospital Cell & Gene Therapy Clinic - Houston
- Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5) - San Antonio
Other
- Novartis Investigative Site - Brussels
- Novartis Investigative Site - Charleroi
- Novartis Investigative Site - Leuven
Georgia
- Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) - Atlanta
- Georgia Regents University Cancer Clinical Research Unit - Augusta
California
- City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(2) - Duarte
Illinois
- Rush University Medical Center Divisionof Hem/Onc Research(2) - Chicago
Maryland
- VA Maryland Health Care Dept.of GreenbaumCancerCent(5) - Baltimore
Massachusetts
- Dana Farber Cancer Institute Hematology / Oncology - Boston
Michigan
- Karmanos Cancer Institute Div.of Hematology/Oncology - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2008-09-16 |
| Est. Completion | 2013-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742027
The ClinicalTrials.gov registry entry for NCT00742027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Classical Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Panobinostat is the first listed.
NCT00742027 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT00742027 about?
NCT00742027 is a clinical study titled "Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma". This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correla...
What is the current status of trial NCT00742027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2008-09-16. Estimated completion is 2013-08-12.
What conditions does trial NCT00742027 study?
This clinical trial studies the following conditions: Classical Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00742027?
The interventions under investigation include: Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00742027?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742027 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.